García, Camilo
Bélgica

Educación Universitaria:
1997: Universidad de Buenos Aires: Diploma de Medico
2001: Université Libre de Bruxelles (revalidación parcial del Diploma Argentino): Docteur en Médecine, Chirurgie et accouchements. 
2006 :Université Libre de Bruxelles : Especialista Universitario en Medicina Nuclear

Otros cursos Universitarions
1998. Curso Superior Universitario, Metodologia en Radio isotopos.  Facultad de Farmacia y Bioquímica. Universidad de Buenos Aires.

Actividad profesional actual

Medico especialista en Medicina Nuclear; social security/INAMI-RIZIV-number: 1-189008-45-970, Bélgica

Jefe de clinica adjunto, Departmento de Medicina Nuclear, Institut Jules Bordet, Bruselas, Bélgica.                                                
Afiliaciones Científicas

Belgian Society of Nuclear Medicine (BELNUC)
European Society of Nuclear Medicine (EANM)
European Society for Molecular Imaging (ESMI)
Society of Nuclear Medicine (SNM)
Asociación Latinoamericana de Tórax (ALAT)
European Lung Cancer Working Party (ELCWP)

Carrera profesional

• Especialidad en Medicina Nuclear del 2001 al 2006, Hospitales Brugmann, Erasme e Institut Bordet, en el cuadro de la formación universitaria de la Universidad Libre de Bruselas.
• Médico de planta del Servicio de Medicina Nuclear, CH Hornu-Frammeries, 10/2006-03/2008
• Médico de planta Servicio de Medicina Nuclear, RHMS Baudour, 04/2008-04/2009
• Médico de planta, Servicio de Medicina Nuclear.  Institut Jules Bordet, Université Libre de Bruxelles,  Bruselas, Bélgica, 10/2006-09/2010
• Jefe de clínica adjunto, Servicio de Medicina Nuclear, Institut  Jules Bordet Université Libre de Bruxelles, Bruselas, Bélgica, 10/2010-now

Grants

• Fundación Bonge & Born: Grant de investigación clínica en medicina respiratoria, Instituto Alfredo Lanari, Universidad de Buenos Aires.   Argentina.

Publicaciones

• Articulos

1.  Surrogate markers predicting overall survival for lung cancer: elcwp recommendations
   Berghmans T, Pasleau F, Paesmans M, Bonduelle Y, Cadranel J, Cs Toth I, Garcia C, Giner V, Holbrechts S, Lafitte JJ, Lecomte J, Louviaux I, Markiewicz E, Meert AP, Richez M, Roelandts M, Scherpereel A, Tulippe C, Van Houtte P, Van Schil P, Wachters C, Westeel V, Sculier JP. Eur Respir J (express). 2011 Jul 7,  as doi: 10.1183/09031936.00190310 (in press)
2. New Imaging Techniques for 90Y Microsphere RadioembolizationMichaël Vouche, Bruno Vanderlinden, Philippe Delatte, Marc Lemort, Alain Hendlisz, Amélie Deleporte, Thomas Guiot, Camilo Garcia
   and Patrick Flamen J Nucl MedRadiat Ther 2:113. doi:10.4172/2155-9619.1000113
3. Positron emission tomography with (18)F-FDG and response to chemotherapy in NSCLC. Van Ruycheveldt V, Garcia C, Meert AP, Berghmans T, Paesmans M,
   Flamen P, Sculier.Rev Mal Respir. 2011 May;28(5):618-625.
4. Detection and Characterization of Tumor Changes in 18F-FDG PET Patient Monitoring Using Parametric Imaging.Hatem Necib, Camilo Garcia, Antoine Wagner, Bruno Vanderlinden,
   Patrick Emonts, Alain Hendlisz, Patrick Flamen, and Irène Buvat. J Nucl
   Med 2011;52 , 354-361.
5. Humanitarian ethics and the notion of justice.Silvia Quadrelli, Henri Colt, Camilo Alejandro Garcia. Can J Public Health.
   2011;102(3):210-14.
6. Imaging of tumour-induced osteomalacia using a gallium-68 labelled somatostatin analogue.Woff E, Garcia C, Tant L, Muylle K,Ghanem G, Bourgeois P, Flamen P. BMJ Case Reports 2010; doi:10.1136/bcr.02.2010.2750
7. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project Paesmans M, Berghmans T, Dusart M, Garcia C, Hossein-Foucher C, Lafitte JJ, Mascaux C, Meert AP, Roelandts M, Scherpereel A, Terrones Munoz V, Sculier JP; European Lung Cancer Working Party, and on behalf of the IASLC Lung Cancer Staging Project. J Thorac Oncol. 2010 May;5(5):612-9.
8. Heterogeneity of Metabolic Response to Systemic Therapy in Metastatic Breast Cancer PatientsHuyge V,  Garcia C,  Alexiou J, Ameye L,  Vanderlinden B, Lemort M, Bergmann P, Awada A,  Body J-J,  Flamen P Clin Oncol (R Coll Radiol). 2010 Dec;22(10):818-27.
9. Progressive osteoblastic bone metastases in breast cancer negative on FDG-PET. Huyge V, Garcia C, Vanderstappen A, Alexiou J, Gil T, Flamen P.Clin Nucl Med. 2009 Jul;34(7):417-20.
10. Nicotine does not compromise resting myocardial blood flow autoregulation in smokers at high cardiovascular risk.
    Argacha JF, Garcia C, Xhaët O, Gujic M, Preumont N, Van Simaeys G, Goldman S, van de Borne P. Nicotine Tob Res. 2008 Jul;10(7):1131-7.
11. Role of positron emission tomography in the management of head and neck cancer in the molecular therapy era.Garcia C, Flamen P. Curr Opin Oncol. 2008 May;20(3):275-9. Review
12. Dural metastases responsible for benign vertebral collapses.Tang BN, Blocklet D, Garcia C, Moreno-Reyes R, Stallenberg B, Goldman S. Eur J Nucl Med Mol Imaging. 2007 Sep;34(9):1515.
13. L-amino acid load to enhance PET differentiation between tumor and inflammation: an in vitro study on (18)F-FET uptake.Laïque S, Egrise D, Monclus M, Schmitz F, Garcia C, Lemaire C, Luxen A, Goldman S.

Libros  (co autor)

Atlas de Mortalidad  por Cancer. Argentina 1989-1992.
Matos, E ; Loria, D ;  Vilensky, M ; Garcia, C. Buenos Aires.  Programa América Latina contra el Cancer. Comité Argentino de Coordinacion, 1997.                                                

Posters,  Presentaciones orales y/o abstracts publicados

1. Are Primary Tumour Standardized Uptake Value, Total lesion glycolysis and metabolic volume  measured on FDG PET(CT) predictors of survival  in advanced Non-Small Cell Lung Cancer? C Garcia, V Terrones, J-P Sculier, P Flamen and T Berghmans.
   2010 World Molecular Imaging Congress. September 8-11, 2010. Kyoto, Japan
   www.wmicmeeting.org/2010/Abstracts/forSystemUse/papers/P1031B.html
2. Comparison of two 68Gallium-labeled octreotide analogues for  molecular PET(CT) imaging of neuroendocrine tumours.
   C Garcia, E Woff, K Muylle, G Ghanem, B Vanderlinden, S Vandormael, E Rutten, P Flamen. European Society for Molecular Imaging. Annual Congress, p138. May 26-29 2010. Warsaw, Poland
3. Positron emission tomography combined with computed tomography (PET-CT) in asymptomatic breast cancer patients showing elevation of circulating tumour markers. C. Garcia, B. Borens-Fefer, K. Muylle, P. Flamen
   European Journal of Cancer 2010 March; 8(3) :P592. Barcelona; Spain.
4. SPECT-CT and the Sentinel Lymph Nodes in Breast cancer patients: additional diagnostic value of CT analysis. P. Bourgeois, C. Garcia, K. Muylle, V. Huyghe, D. Hertens, D. Noterman, F. Deneubourg, I. Veys, J. Nogaret, D. Larsimont, M. Lemort, P. Flamen
   Eur J Nucl Med Mol Imaging (2009) 36 (Suppl 2): P325. EANM Congress. Barcelona, Spain.
5. Which threshold should be used to detect SUV change in FDG-PET patient monitoring? H. Necib, C. Garcia, A. Wagner, A. Hendlisz, P. Flamen, I. Buvat. J. Nucl. Med. 51, 1177, 2010. SNM Congress, Salt Lake City; USA.
6. The role of FDG PET(CT) for diagnosis of peritoneal carcinomatosis of colorectal origin  G. Liberale, C. Lecocq, C. Garcia, K. Muylle, A. Covas, G. Andry, I. El Nakadi, P. Flamen. ECCO 15 - ESMO 34. September 20-24 2009. Berlin Germany
7. Assessing response to chemotherapy in advanced non small cell lung cancer (NSCLC) : morphological or metabolic criteria ? V. Van Ruychevelt, C. Garcia, M. Paesmans, T. Berghmans, A.P. Meert, N. Leclercq, P. Flamen, J.P. Sculier.
   13th World Conference on Lung Cancer, San Francisco, USA, 2009
8. An updated meta-analysis (MA) of the literature assessing the prognostic role of primary tumour standardized uptake value (SUV) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) in non-small cell lung cancer (NSCLC). A study by the European Lung Cancer Working Party for the IASLC Staging Project. T. Berghmans, M. Paesmans, M. Dusart, C. Garcia, C. Hossein-Foucher, J.J. Lafitte, C. Mascaux, A.P. Meert, M. Roelandts, A. Scherpereel, V. Terrones Munoz and J.P. Sculier
   13th World Conference on Lung Cancer, San Francisco, USA, 2009
9. Diagnostic accuracy of 89Zr-rituximab-PET/CT imaging in patients with relapsed CD20+ B-Cell non-Hodgkin’s lymphoma: comparison with 18FDG-PET/CT. K. Muylle, D. J. Vugts, C. Garcia, B. Doornaert, G. Ghanem, P. Bourgeois, B. Vanderlinden, G.A.M.S. van Dongen, D. Bron, P. Flamen
   Belgian Society of Nuclear Medicine. Bruges; May 15-17, 2009
10. Role of FDG-PET/CT in Hodgkin’s lymphomas: clinical assessment in a single center. G. Leurquin-stek, K. Muylle, N. Meuleman, C. Garcia, C. Ravoet, C. Springael, A. Vanderstappen, P. Flamen, D. Bron.
    Belgian Hematology Society. January 30, 2009: P28
11. 68Ga-DOTATOC PET/CT in recurrent medullary thyroid carcinoma. K. Muylle, C. Garcia, A. Vanderstappen, G. Ghanem, B. Vanderlinden, P. Bourgeois, P. Flamen
    Belgian Society of Nuclear Medicine. June 4-6, 2007.
12. Can we predict the ablation of thyroid tissues after 131-Iodine treatment for differentiated thyroid carcinomas (DTC)? Preliminary analysis. P. Bourgeois, K. Muylle, C. Garcia, B. Vanderlinden, P. Flamen
    Belgian Society of Nuclear Medicine. June 4-6, 2007.
13. FDG PET predicts prognosis of patients with resectable metastatic colorectal cancer (CRC) treated with preoperative chemotherapy.
    P. Flamen, V. Huberty, C. Garcia, B. Vanderlinden, K. Muylle, H. Legendre, M. Paesmans, M. Van Den Eynde, A. Hendlisz Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 14540